Posted by Michael Wonder on 28 May 2025
New subcutaneous formulation of Opdivo approved in Canada for use across all authorised solid tumour indications
27 May 2025 - Subcutaneous option of established immunotherapy offers potential to reduce time in clinic and ease infusion burden.
Bristol Myers Squibb Canada today announced that Health Canada has approved Opdivo SC (nivolumab for subcutaneous injection) across all currently authorised solid tumour indications in monotherapy, in the maintenance phase following combination with ipilimumab (Yervoy), and in combination regimens with chemotherapy or tyrosine kinase inhibitors, consistent with the indications approved for the intravenous formulation.
